Abstract
Objective: The case aims to show anti-proteinuric effect of Chinese herbal medicines (CHM) in a patient with heavy proteinuric non-IgA mesangial proliferative glomerulonephritis (MsPGN). Subject: A 16-year-old boy was found edema in the lower limbs and a great quantity of urine protein for 4-months and diagnosed as non-IgA MsPGN via renal biopsy later, but there was no amelioration after receiving a shortdated comprehensive treatment including full amount of prednisone. Then he visited Prof. Ming Wan for traditional Chinese medicine (TCM) therapy. Interventions and outcome: This patient was treated with the integrated treatment, mainly including empirical Chinese herbal formulas (500 mL/day for 3-months), multi-glycoside of Tripterygium wilfordii Hook.f. (GTW) (90 mg/day for 3-months) and Losartan (50 mg/day for 3-months). His heavy proteinuria and clinical conditions were significantly improved after continuous treatment for 3-months and basically stable for nearly 3-years during the follow-up. Conclusions: Based on a variety of conventional drugs in clinic, the combined treatment of empirical Chinese herbal formulas and GTW was significantly effective in reducing massive proteinuria in non-IgA MsPGN patients, which is different from hormonotherapy.
Keywords: Case report, Chinese herbal medicines, multi-glycoside of Tripterygium wilfordii Hook.f. (GTW), Non-IgA mesangial proliferative glomerulonephritis, proteinuria.
Current Traditional Medicine
Title:A Case of Heavy Proteinuric Non-IgA Mesangial Proliferative Glomerulonephritis Ameliorated by Chinese Herbal Medicines
Volume: 1 Issue: 3
Author(s): Yan-ru Huang, Thomas Heaton, Yi-gang Wan, Zhi-min Mao and Jing-jing Yang
Affiliation:
Keywords: Case report, Chinese herbal medicines, multi-glycoside of Tripterygium wilfordii Hook.f. (GTW), Non-IgA mesangial proliferative glomerulonephritis, proteinuria.
Abstract: Objective: The case aims to show anti-proteinuric effect of Chinese herbal medicines (CHM) in a patient with heavy proteinuric non-IgA mesangial proliferative glomerulonephritis (MsPGN). Subject: A 16-year-old boy was found edema in the lower limbs and a great quantity of urine protein for 4-months and diagnosed as non-IgA MsPGN via renal biopsy later, but there was no amelioration after receiving a shortdated comprehensive treatment including full amount of prednisone. Then he visited Prof. Ming Wan for traditional Chinese medicine (TCM) therapy. Interventions and outcome: This patient was treated with the integrated treatment, mainly including empirical Chinese herbal formulas (500 mL/day for 3-months), multi-glycoside of Tripterygium wilfordii Hook.f. (GTW) (90 mg/day for 3-months) and Losartan (50 mg/day for 3-months). His heavy proteinuria and clinical conditions were significantly improved after continuous treatment for 3-months and basically stable for nearly 3-years during the follow-up. Conclusions: Based on a variety of conventional drugs in clinic, the combined treatment of empirical Chinese herbal formulas and GTW was significantly effective in reducing massive proteinuria in non-IgA MsPGN patients, which is different from hormonotherapy.
Export Options
About this article
Cite this article as:
Huang Yan-ru, Heaton Thomas, Wan Yi-gang, Mao Zhi-min and Yang Jing-jing, A Case of Heavy Proteinuric Non-IgA Mesangial Proliferative Glomerulonephritis Ameliorated by Chinese Herbal Medicines, Current Traditional Medicine 2015; 1 (3) . https://dx.doi.org/10.2174/221508380103151231142116
DOI https://dx.doi.org/10.2174/221508380103151231142116 |
Print ISSN 2215-0838 |
Publisher Name Bentham Science Publisher |
Online ISSN 2215-0846 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Trebananib (AMG 386): A Non-VEGF Antiangiogenesis Option in Women with Ovarian Cancer
Current Angiogenesis (Discontinued) Prolylcarboxypeptidase Gene Expression in the Heart and Kidney: Effects of Obesity and Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Non-Suicidal Self-Injury in an Adolescent: A Case Report and Discussion of Treatment
Adolescent Psychiatry Dietary Patterns in Alzheimers Disease and Cognitive Aging
Current Alzheimer Research Endothelial Dysfunction in Sepsis
Current Vascular Pharmacology How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?
Current Cardiology Reviews In Vitro and In Vivo Assessment of Matrix Type Transdermal Therapeutic System of Labetalol Hydrochloride
Current Drug Delivery Glaucoma: Validated and Facile In Vivo Experimental Models of a Chronic Neurodegenerative Disease for Drug Development
Current Medicinal Chemistry - Central Nervous System Agents Endothelium Dependent and Independent Mechanisms of Vasorelaxant Activity of Synthesized 2,5-disubstituted-1,3,4-oxadiazole Derivatives in Rat Thoracic Aorta – Ex vivo and Molecular Docking Studies
Letters in Drug Design & Discovery Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews Metabolic Syndrome and Diabetic Atherothrombosis: Implications in Vascular Complications
Current Molecular Medicine Does HbA1cc Play a Role in the Development of Cardiovascular Diseases?
Current Pharmaceutical Design Human Copper Chaperone Atox1 Translocates to the Nucleus but does not Bind DNA In Vitro
Protein & Peptide Letters Regulatory T Cells and Tolerogenic Dendritic Cells as Critical Immune Modulators in Atherogenesis
Current Pharmaceutical Design Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Estimation of Familial Combined Hyperlipoproteinemia Prevalence in a Large Rural Population: The Brisighella Heart Study
Vascular Disease Prevention (Discontinued) Gender Differences in Liver Fibrosis and Hepatitis C Virus-Related Parameters in Patients Coinfected with Human Immunodeficiency Virus
Current HIV Research Effect of Colestimide on Reduction of Body Weight and Waist Circumference in Metabolic Syndrome Patients with Cardiovascular Risk Factors
Vascular Disease Prevention (Discontinued)